Finerenone Cardiorenal: Robust Effects on 4 Outcomes
How FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF reframe mineralocorticoid receptor antagonism across CKD, type 2 diabetes, and heart failure with preserved ejection fraction.
One-Minute Takeaway on Finerenone Cardiorenal Evidence
- The finerenone cardiorenal program — FIDELIO-DKD, FIGARO-DKD, and the prespecified FIDELITY pooled analysis — provides strong evidence that this nonsteroidal mineralocorticoid receptor antagonist reduces kidney progression and major cardiovascular events in patients with chronic kidney disease and type 2 diabetes.
- FINEARTS-HF extends benefit to heart failure with mildly reduced or preserved ejection fraction, with a rate ratio of 0.84 (95% CI 0.74–0.95) for total worsening heart failure events and cardiovascular death.
- Pooled FIDELITY data show a kidney composite hazard ratio of 0.77 (95% CI 0.67–0.88) and a cardiovascular composite hazard ratio of 0.86 (95% CI 0.78–0.95) across more than 13,000 patients.
- Hyperkalemia is the main practical limit. Treatment-emergent rates are roughly doubled compared with placebo, but permanent discontinuations remained below 2% when potassium monitoring followed the trial protocols.
Why Finerenone Cardiorenal Trials Matter for Clinical Practice
Patients with chronic kidney disease and type 2 diabetes carry one of the highest combined risks of kidney failure and cardiovascular events in clinical medicine. Even on maximally tolerated renin-angiotensin system blockade and modern glycemic control, residual risk remains substantial. The finerenone cardiorenal program was designed specifically to address that gap.
Classical steroidal mineralocorticoid receptor antagonists — spironolactone and eplerenone — have shown clear benefit in heart failure with reduced ejection fraction. Their use in chronic kidney disease has been constrained by hyperkalemia, antiandrogenic side effects, and a limited evidence base for kidney endpoints. Finerenone is a nonsteroidal MRA with a different tissue distribution and a more balanced kidney-versus-cardiac binding profile.
Three large randomized trials and a prespecified pooled analysis now anchor the finerenone cardiorenal evidence base. FIDELIO-DKD focused on kidney outcomes in more advanced albuminuric CKD with T2DM. FIGARO-DKD focused on cardiovascular outcomes in a broader, earlier-stage CKD population. FINEARTS-HF extends the question into heart failure with preserved or mildly reduced ejection fraction.
For internal medicine clinicians managing layered cardiorenal risk, the practical question is not whether the drug works, but where it fits alongside SGLT2 inhibitors, GLP-1 receptor agonists, and standard renin-angiotensin system blockade. The finerenone cardiorenal trials begin to answer that question across the full spectrum from albuminuric CKD to HFpEF.
Evidence Reviewed
The finerenone cardiorenal evidence base rests on three large pivotal trials and one prespecified pooled analysis. Each pivotal trial used a placebo-controlled, double-blind design on top of optimized background therapy, including maximally tolerated renin-angiotensin system blockade.
| Trial | Population | N | Primary Outcome | Result (95% CI) |
|---|---|---|---|---|
| FIDELIO-DKD | T2DM + CKD (eGFR 25–75, UACR 30–5000), on optimized ACEi/ARB | 5,734 | Kidney composite: kidney failure, sustained ≥40% eGFR decline, or renal death | HR 0.82 (0.73–0.93) |
| FIGARO-DKD | T2DM + CKD (broader, earlier-stage), on optimized ACEi/ARB | 7,437 | CV composite: CV death, nonfatal MI, nonfatal stroke, HF hospitalization | HR 0.87 (0.76–0.98) |
| FIDELITY | Prespecified pooled analysis of FIDELIO + FIGARO | 13,026 | CV composite and kidney composite | CV: 0.86 (0.78–0.95); Kidney: 0.77 (0.67–0.88) |
| FINEARTS-HF | Heart failure with LVEF ≥40% (HFmrEF + HFpEF) | 6,001 | Total worsening HF events + cardiovascular death | RR 0.84 (0.74–0.95) |
Several preplanned questions inform interpretation of the finerenone cardiorenal trials. The accordions below summarize the mechanism, the eGFR trajectory clinicians should expect, exclusion criteria that affect generalizability, and how findings interact with SGLT2 inhibitor use.
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist with a distinctive bulky structure that confers passive antagonism of the receptor. Its tissue distribution is more balanced between heart and kidney compared with steroidal MRAs, and it has minimal affinity for androgen, progesterone, or glucocorticoid receptors.
The clinical signature in trials is reduced gynecomastia and breast tenderness compared with high-dose spironolactone, with hyperkalemia rates lower than typically seen at comparable mineralocorticoid receptor blockade. Whether these properties translate into superior hard-outcome effects versus steroidal MRAs in CKD remains untested in head-to-head randomized trials.
FIDELIO-DKD and FIGARO-DKD both showed an early, predominantly hemodynamic decline in eGFR within the first four months of treatment, followed by stabilization. The long-term eGFR slope favored finerenone, consistent with a drug-induced reduction in glomerular hyperfiltration.
The pattern mirrors what is seen with ACE inhibitors, ARBs, and SGLT2 inhibitors. Clinically, an eGFR drop of up to 30% in the first months is generally not a reason to discontinue therapy if blood pressure is stable and serum potassium is controlled.
Common exclusions in FIDELIO and FIGARO included serum potassium above 4.8 mmol/L at screening, symptomatic chronic heart failure with reduced ejection fraction (which was an established indication for steroidal MRA), known nondiabetic kidney disease, and recent dialysis. FINEARTS-HF excluded patients with current MRA use within four weeks of randomization.
Real-world patients with elevated baseline potassium, active heart failure with reduced ejection fraction, or eGFR below 25 ml/min/1.73m² were therefore underrepresented or excluded. Extending finerenone use into these populations carries weaker evidentiary support.
Background SGLT2 inhibitor use was modest in FIDELIO (under 5%) and somewhat higher in FIGARO (under 10%), reflecting prescribing patterns when those trials were enrolling. Prespecified subgroup analyses suggested finerenone’s effects on kidney and cardiovascular endpoints were broadly consistent regardless of baseline SGLT2 inhibitor use.
Mechanistic considerations also support combination: SGLT2 inhibitors and nonsteroidal MRAs act through largely distinct pathways. Short-term combination trials have shown additive albuminuria reduction; mortality and kidney failure data for the combination await longer-term dedicated trials.
Key Findings by Theme
Across the finerenone cardiorenal program, four themes emerge consistently. The signals appear in different populations and trial designs, but the directions and magnitudes of effect align.
Concordant slowing of CKD progression
In FIDELIO-DKD, the kidney composite of kidney failure, sustained ≥40% eGFR decline, or renal death occurred less often with finerenone, with a hazard ratio of 0.82 (95% CI 0.73–0.93). The harder kidney endpoint of kidney failure or sustained ≥57% eGFR decline showed a larger relative effect when assessed in the FIDELITY pooled analysis, with a hazard ratio of 0.77 (95% CI 0.67–0.88).
Both trials enrolled patients on maximally tolerated ACE inhibitors or ARBs at baseline, so the kidney effects are incremental to standard renin-angiotensin system blockade. The effect was consistent across baseline UACR strata, eGFR strata, and glycemic control levels, supporting broad generalizability within the trial population.
Cardiovascular benefit driven largely by reduced HF hospitalization
FIGARO-DKD met its primary cardiovascular endpoint with a hazard ratio of 0.87 (95% CI 0.76–0.98). The treatment effect was driven mainly by a reduction in heart failure hospitalization, with a hazard ratio of 0.71 (95% CI 0.56–0.90) for that component. Smaller, statistically non-significant trends were observed for myocardial infarction and stroke.
In the FIDELITY pooled analysis, the four-point cardiovascular composite showed a hazard ratio of 0.86 (95% CI 0.78–0.95). The heart failure hospitalization signal again carried much of the effect within the finerenone cardiorenal program, anticipating what FINEARTS-HF would later confirm in a dedicated heart failure population.
HFpEF and HFmrEF: extending the cardiorenal axis
FINEARTS-HF enrolled 6,001 patients with heart failure and LVEF ≥40%, with or without type 2 diabetes and with or without CKD. The primary composite of total worsening heart failure events and cardiovascular death occurred less often with finerenone, with a rate ratio of 0.84 (95% CI 0.74–0.95).
The benefit was consistent across LVEF subgroups, including patients with EF 40–49% and EF ≥60%, and across baseline diuretic use. The signal positions finerenone alongside SGLT2 inhibitors as a disease-modifying option for heart failure with preserved ejection fraction, a population that has historically had limited pharmacologic choices.
Hyperkalemia: the predictable safety signal
All three pivotal finerenone cardiorenal trials showed higher rates of treatment-emergent hyperkalemia with finerenone than with placebo. In the FIDELITY pooled analysis, serum potassium above 5.5 mmol/L occurred in roughly 14% of finerenone-treated patients versus 6% of placebo. Hospitalization for hyperkalemia and permanent discontinuation for hyperkalemia were both uncommon, generally below 2%.
The trials used structured potassium monitoring with dose-adjustment thresholds, a practice now embedded in regulatory labels. Outside trial conditions, hyperkalemia incidence may be higher when monitoring is less rigorous, particularly in patients with lower eGFR or those on concomitant agents that raise potassium.
Quality and Consistency of the Finerenone Cardiorenal Evidence
The finerenone cardiorenal evidence base meets the methodological standards expected of a disease-modifying therapy. Concordance across populations is its strongest feature; representation gaps are its main weakness.
What the Evidence Does Not Yet Show
Despite the breadth of the finerenone cardiorenal program, several specific gaps remain. Naming them sharpens clinical reasoning and identifies where ongoing trials may shift practice.
Specific gaps
- No head-to-head RCT versus steroidal MRAs for hard kidney or cardiovascular outcomes. The phase 2 ARTS-HF program compared finerenone with eplerenone for short-term tolerability and biomarkers, not long-term outcomes.
- Non-diabetic CKD outcomes are not yet fully addressed for hard endpoints. Albuminuria-focused data exist, but kidney failure and mortality outcomes in non-diabetic CKD are still maturing.
- Combination outcome data with SGLT2 inhibitors for kidney failure and cardiovascular death await dedicated trials. Short-term combination studies have shown additive albuminuria reduction.
- Long-term safety beyond approximately three years of follow-up. Most pivotal trials had a median follow-up of two to three years.
- Pediatric and adolescent populations with CKD and T2DM were not enrolled in the pivotal trials.
- Patients with eGFR below 25 ml/min/1.73m² and those on dialysis were excluded and have no high-quality evidence base for finerenone use.
Each gap maps to an ongoing or planned trial program. Clinicians should expect the evidence base on combination therapy and non-diabetic CKD to mature substantially over the next several years.
Practical Implications for CKD with Type 2 Diabetes
Within the population represented by the finerenone cardiorenal trials, the evidence supports specific implementation patterns. The framing below is evidence-based rather than prescriptive: individual clinical judgment and patient preference remain central.
Evidence Supports Finerenone in T2DM with Albuminuric CKD on RAS Blockade
FIDELIO-DKD and FIGARO-DKD both enrolled patients with T2DM, eGFR generally above 25 ml/min/1.73m², and persistent albuminuria despite optimized ACE inhibitor or ARB therapy. The pooled hazard ratios for kidney progression and cardiovascular events support adding finerenone in this exact phenotype.
FINEARTS-HF Supports Use in HFpEF and HFmrEF Beyond Diabetes
In FINEARTS-HF, the effect on worsening heart failure events and cardiovascular death was consistent across patients with and without T2DM and across patients with and without CKD. This extends finerenone’s evidence base beyond the original CKD with T2DM indication into the broader HFpEF population.
Potassium Monitoring Protocols Mirror Trial Practices
Trial protocols measured serum potassium at baseline, four weeks after initiation, four weeks after each dose change, and periodically thereafter. Dose reduction or interruption was triggered at potassium ≥5.5 mmol/L. Reproducing this monitoring cadence in clinic appears to keep hyperkalemia rates within trial ranges.
Concordant Effects Across the Axis Support Layered Therapy
The finerenone cardiorenal program shows effects that are largely additive to renin-angiotensin system blockade, with mechanistic distinction from SGLT2 inhibition and GLP-1 receptor agonism. Where layered therapy is tolerated, the available evidence supports combination rather than substitution for most patients with CKD and T2DM.
Implementation also depends on practical factors: cost and access, baseline potassium and blood pressure, polypharmacy considerations, and patient capacity for follow-up labs. Shared decision-making remains central, particularly when finerenone is layered on multiple other cardiorenal therapies.
Evidence Grade and Bottom Line
Evidence Grade: Strong evidence supports finerenone for kidney and cardiovascular outcomes in CKD with type 2 diabetes. Moderate-to-strong evidence supports its use in heart failure with mildly reduced or preserved ejection fraction. The hyperkalemia signal is predictable and manageable with structured monitoring at protocol-defined intervals.
The overall picture across the finerenone cardiorenal evidence base is that of a disease-modifying therapy with concordant effects across kidney, cardiovascular, and heart failure endpoints. The remaining uncertainty concerns optimal sequencing, combination outcomes, and use in populations excluded from pivotal trials.
Bottom Line
- Three large randomized trials and a prespecified pooled analysis support finerenone as a disease-modifying option across the cardiorenal axis, from albuminuric CKD with T2DM to heart failure with preserved or mildly reduced ejection fraction.
- Effect sizes are clinically meaningful and concordant across kidney progression, cardiovascular events, and worsening heart failure outcomes, with hazard or rate ratios clustered between 0.77 and 0.87.
- Hyperkalemia is predictable, dose-dependent, and largely controllable with structured potassium monitoring at protocol-defined intervals and at baseline potassium under 4.8 mmol/L.
- Most of the trial population was already on renin-angiotensin system blockade, so the observed benefits are incremental to that standard rather than substitutive.
- Open questions include optimal sequencing with SGLT2 inhibitors, combination outcome data for kidney failure and cardiovascular death, and hard outcome evidence in non-diabetic CKD populations.
Article Information and References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England Journal of Medicine. 2020;383(23):2219-2229. DOI: 10.1056/NEJMoa2025845
- Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. New England Journal of Medicine. 2021;385(24):2252-2263. DOI: 10.1056/NEJMoa2110956
- Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine. 2024;391(16):1475-1485. DOI: 10.1056/NEJMoa2407107
- Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal. 2022;43(6):474-484. DOI: 10.1093/eurheartj/ehab777
- Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143(6):540-552. DOI: 10.1161/CIRCULATIONAHA.120.051898
- Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial (ARTS-DN). JAMA. 2015;314(9):884-894. DOI: 10.1001/jama.2015.10081
- Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone versus eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease (ARTS-HF). European Heart Journal. 2016;37(27):2105-2114. DOI: 10.1093/eurheartj/ehw132
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022;102(5S):S1-S127. DOI: 10.1016/j.kint.2022.06.008
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063